Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Lung Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

LDCT was performed at baseline + 2 biennial repeated LDCT rounds

LDCT were performed in screening arm. The abnormal nodules were defined as noncalcified nodules (NCN) larger than 5 mm

Low Dose Computed Tomography

AI was performed in high-risk individuals recruitment and lung nodules management

artificial intelligence (AI)

AFI applied in screening of centrally located SCC.

autofluorescence imaging (AFI)

Baohui Han, MD Dr.

Yanwei Zhang, MD Dr.

Baohui Han

Our previous study, china lung cancer screening study version 1.0, had proven that LDCT led to a 74.1% increase in detecting early-stage lung cancer compare to usual care (NCT02898441). The present one arm study is performed to evaluate the efficacy of new techniques in improving the implementation of lung cancer screening and validate our previous findings. 6000 high-risk subjects (age 45-75) were recruited to take LDCT screening. (Baseline + 2 biennial repeated LDCT screening). Follow-up for lung cancer incidence, lung cancer mortality and overall mortality was performed. Blood samples were stored in a Biobank. Management of positive screening test was carried out by a pre-specified protocol.

China Lung Cancer Screening (CLUS) Study Version 2.0

Community-based Lung Cancer Screening With Low-dose CT in China (CLUS Study) Version 2.0

Assess lung cancer mortality within next 5 years after first round of screening

Evaluate the ability of AI in enhancing the attendance rate of high-risk individuals

Evaluate the ability of AI, AFI and molecular biomarkers in enhancing the diagnostic accuracy rate of lung cancer

Assess all-cause mortality within next 5 years after first round of screening

Assess lung nodules detection rate, and the types and sizes of nodules detected in LDCT screening

Assess the number of lung cancer incidences after each round of screening

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
China Lung Cancer Screening (CLUS) Study Version 2.0	NCT03975504	Lung Neoplasms	Low Dose Comput... artificial inte... autofluorescenc...	45 Years - 75 Years	Shanghai Chest Hospital
China Lung Cancer Screening (CLUS) Study Version 2.0	NCT03975504	Lung Neoplasms	Low Dose Comput... artificial inte... autofluorescenc...	45 Years - 75 Years	Shanghai Chest Hospital
China Lung Cancer Screening (CLUS) Study Version 2.0	NCT03975504	Lung Neoplasms	Low Dose Comput... artificial inte... autofluorescenc...	45 Years - 75 Years	Shanghai Chest Hospital
China Lung Cancer Screening (CLUS) Study Version 2.0	NCT03975504	Lung Neoplasms	Low Dose Comput... artificial inte... autofluorescenc...	45 Years - 75 Years	Shanghai Chest Hospital

Spots Global Cancer Trial Database for autofluorescence imaging (afi)